dMMR/MSI-H Rectal Cancer

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

dMMR/MSI-H Rectal Cancer

Dec 21, 2024, 05:01 | Insight

FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer

The FDA has granted Breakthrough Therapy Designation (BTD) to dostarlimab for the treatment of patients…

All: 1 Posts: 1 - 100

'

FDA Approves Penpulimab for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma

'

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

'

Where to Study to Become ASCO President: 2025 Institutional Rankings

'

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

'

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023